Magnesium-based resorbable scaffold vs permanent metallic sirolimus-eluting stent in patients with ST-segment elevation myocardial infarction: 3-year results of the MAGSTEMI randomised controlled trial.

Plain-language guide to PMID 35225793 (2022): single-blind randomized controlled trial of Vitamin D, K2, Magnesium and Zinc.

Key Facts

PMID: 35225793
Journal: EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology
Year: 2022
Study type: Randomized Controlled Trial
Authors: Ortega-Paz L et al. (16 authors)
DOI: 10.4244/EIJ-D-21-00651

What This Study Did, in Plain Language

What Was Tested

The paper reports a study of Vitamin D, K2, Magnesium and Zinc, published as a randomized controlled trial.

The aim of this study was to report the 3-year clinical outcomes of the MAGSTEMI trial.

Why It Was Studied

The long-term safety and performance of magnesium-based bioresorbable scaffolds (MgBRS) in ST-segment-elevation myocardial infarction (STEMI) patients are uncertain.

Who Took Part

This investigator-driven, multicentre, randomised, single-blind, controlled trial randomised STEMI patients 1:1 to MgBRS or to permanent metallic sirolimus-eluting stents (SES) at 11 academic centres.

The main secondary endpoints included device-oriented composite endpoints (DoCE) and patient-oriented composite endpoints (PoCE), their individual components, any bleeding, and device thrombosis rate.

How the Study Was Run

The design is described as randomized, single-blind and multicenter.

Random assignment meant chance, not the researchers, decided who got Vitamin D, K2, Magnesium and Zinc and who got the comparison, which limits bias.

In this single-blind Vitamin D, K2, Magnesium and Zinc study one party knew the assignments and the other did not.

More than one site took part, so the participants came from several places.

All endpoints were defined according to the Academic Research Consortium.

Events were adjudicated by an independent committee.

What Was Measured

Topics PubMed links to this paper include Absorbable Implants, Drug-Eluting Stents, Magnesium, ST Elevation Myocardial Infarction, Sirolimus and Stents.

What This Means in Plain Language

The paper is a randomized, single-blind and multicenter study of Vitamin D, K2, Magnesium and Zinc.

Results are reported in around 7 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2022 (EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology), a journal based in France.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.

Our Notes on the Compound

Vitamin D, K2, Magnesium and Zinc: Magnesium is described as required for AMPK to function.

Vitamin D, K2, Magnesium and Zinc in the library

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.